UBS Oconnor LLC
- SEC CIK
- 0001132716
- Latest filing
- Aug 14, 2026
RVNC holding history
Revance Therapeutics, Inc. in every 13F filed by UBS Oconnor LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RVNC overviewAll 13F holders of RVNCFull Q4 2025 holdings
- Shares (Q3 2024)
- 0
- Sold out in Q3 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 7
- Since Q2 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2024 | 0 | $0 | 0.0% | −325,314−100.0% | Sold out | Holders |
| Q2 2024 | 325,314 | $836.1K | <0.1% | +70,647+27.7% | Added | Holders |
| Q1 2024 | 254,667 | $1.25M | <0.1% | +145,000+132.2% | Added | Holders |
| Q4 2023 | 109,667 | $964.0K | <0.1% | +20,867+23.5% | Added | Holders |
| Q3 2023 | 88,800 | $1.02M | <0.1% | +88,800 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −20,214−100.0% | Sold out | Holders |
| Q1 2023 | 20,214 | $651.1K | <0.1% | +20,214 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −101,179−100.0% | Sold out | Holders |
| Q3 2022 | 101,179 | $2.73M | <0.1% | −74,000−42.2% | Reduced | Holders |
| Q2 2022 | 175,179 | $2.42M | <0.1% | +175,179 | New | Holders |